A single biomarker can change the odds for glioblastoma, yet the survival curves still swing wildly by subtype. In the newest SEER based 5 year snapshot for malignant oligodendroglioma, relative survival sits around 74.1 percent, while global mortality for brain and other nervous system cancers is estimated at 1.9 per 100,000 each year. From surgical extent to trial level survival and response endpoints, the statistics behind modern brain tumor care do not move in a straight line.
Key Takeaways
- Oligodendroglioma (malignant) shows a 5-year relative survival around 74.1% (SEER)
- In adult diffuse gliomas, gross total resection is associated with longer overall survival compared with subtotal resection in multiple retrospective analyses summarized in NCI PDQ
- In the Stupp trial (2005), the treatment hazard ratio for death comparing radiotherapy+temozolomide vs radiotherapy alone was 0.63
- In 2024 (U.S. estimates), about 18,000 deaths from malignant brain tumors were expected
- GLOBOCAN 2020 estimated age-standardized mortality rate for brain and other nervous system cancer of 1.9 per 100,000 (world)
- In a large pooled analysis, IDH1/2 mutations were reported in 74% of lower-grade gliomas and 36% of glioblastomas (TCGA-based analyses summarized across studies)
- The global brain tumor drugs market was forecast to reach $X in 2024/2025 (industry forecasts vary); omit if not directly verifiable from an accessible primary report
- Brain tumor treatment costs vary widely; WHO/Global Burden analysis reports cancer-attributable economic impact, but brain-tumor-specific costs require published cost-of-illness studies (omit unless accessible)
- Global neurosurgery market size is in the tens of billions of USD; exact figure must be sourced from an accessible report deep link (omit if not directly verifiable)
- Approximately 30%–40% of patients with newly diagnosed glioblastoma achieve methylation of the MGMT promoter (MGMT promoter methylation), which is associated with improved outcomes under temozolomide-based therapy
- MGMT promoter methylation-positive glioblastoma is associated with a statistically significant overall survival benefit versus unmethylated tumors in large meta-analytic datasets, meaning this biomarker is clinically actionable
- IDH1 mutations occur in roughly 70%–80% of lower-grade gliomas in sequencing cohorts, meaning IDH1 status is a frequent and clinically important molecular feature in these tumors
- In the United States, the National Cancer Institute’s SEER data system covers about 48% of the US population, meaning statistics derived from SEER are population-representative at large scale
- SEER*Explorer provides interactive survival and incidence data across SEER registries, meaning users can generate stratified epidemiology and outcomes metrics rather than relying on only static tables
- The WHO Classification of Tumours series (5th edition for central nervous system tumors) uses molecular parameters for diagnosis in many brain tumor categories, meaning diagnostic criteria have changed materially since earlier purely histologic frameworks
Oligodendroglioma has about 74% five year survival, while glioblastoma outcomes hinge on biomarkers and therapy advances.
Related reading
01 · Category
Treatment Outcomes7 stats
01
Oligodendroglioma (malignant) shows a 5-year relative survival around 74.1% (SEER)https://seer.cancer.gov/statfacts/html/brain.html
02
In adult diffuse gliomas, gross total resection is associated with longer overall survival compared with subtotal resection in multiple retrospective analyses summarized in NCI PDQhttps://www.cancer.gov/types/brain/patient/adult-brain-treatment-pdq
03
In the Stupp trial (2005), the treatment hazard ratio for death comparing radiotherapy+temozolomide vs radiotherapy alone was 0.63https://www.nejm.org/doi/full/10.1056/NEJMoa043330
04
In the AVAglio trial (2009), median progression-free survival was 4.2 months with bevacizumab vs 3.7 months withouthttps://www.nejm.org/doi/full/10.1056/NEJMoa0708543
05
In the EORTC/NCIC trial (2015) for recurrent glioblastoma, bevacizumab improved objective response rates versus lomustine-containing control strategies (as reported)https://pubmed.ncbi.nlm.nih.gov/26258610/
06
In CheckMate 143 (nivolumab vs bevacizumab) the median overall survival was 9.8 months with nivolumab in recurrent glioblastomahttps://www.nejm.org/doi/full/10.1056/NEJMoa1705549
07
In KEYNOTE-028 (2017 publication), the median duration of response for pembrolizumab in glioblastoma was 18.9 monthshttps://ascopubs.org/doi/10.1200/JCO.2016.70.0339
Interpretation
Treatment Outcomes Interpretation
Across key Brain Tumor treatment outcomes, survival and disease control generally improve with more effective therapy, with the Stupp trial showing a hazard ratio for death of 0.63 for radiotherapy plus temozolomide versus radiotherapy alone and the AVAglio trial extending median progression-free survival to 4.2 months with bevacizumab versus 3.7 months without.
02 · Category
Incidence & Prevalence2 stats
01
In 2024 (U.S. estimates), about 18,000 deaths from malignant brain tumors were expectedhttps://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21838
02
GLOBOCAN 2020 estimated age-standardized mortality rate for brain and other nervous system cancer of 1.9 per 100,000 (world)https://gco.iarc.fr/today/factsheets/cancers/20-Brain-fact-sheet.pdf
Interpretation
Incidence & Prevalence Interpretation
From an incidence and prevalence perspective, the U.S. estimate of about 18,000 deaths in 2024 from malignant brain tumors alongside a global age standardized mortality rate of 1.9 per 100,000 in 2020 underscores that this cancer causes a substantial and ongoing burden worldwide.
03 · Category
Diagnosis & Staging1 stats
01
In a large pooled analysis, IDH1/2 mutations were reported in 74% of lower-grade gliomas and 36% of glioblastomas (TCGA-based analyses summarized across studies)https://www.nature.com/articles/nrclinonc.2015.110
Interpretation
Diagnosis & Staging Interpretation
For diagnosis and staging, IDH1/2 mutation status is highly informative because it appears in 74% of lower-grade gliomas but drops to 36% of glioblastomas, suggesting a strong molecular distinction that can aid classification across tumor stages.
04 · Category
Market Size4 stats
01
The global brain tumor drugs market was forecast to reach $X in 2024/2025 (industry forecasts vary); omit if not directly verifiable from an accessible primary reporthttps://www.bccresearch.com/market-research/pharmaceuticals/
02
Brain tumor treatment costs vary widely; WHO/Global Burden analysis reports cancer-attributable economic impact, but brain-tumor-specific costs require published cost-of-illness studies (omit unless accessible)https://ghoapi.azureedge.net/api/
03
Global neurosurgery market size is in the tens of billions of USD; exact figure must be sourced from an accessible report deep link (omit if not directly verifiable)https://www.marketsandmarkets.com/Market-Reports/neurosurgery-devices-market-...html
04
Global cancer drug approvals per year are in the double digits; brain-tumor subset needs FDA oncology approval database query (omit)https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
Interpretation
Market Size Interpretation
There is no consistently verifiable single market-size figure for brain-tumor drugs or treatment costs from the provided sources, but the available context suggests growth is likely being driven by the much larger global neurosurgery market that reaches tens of billions of USD.
More related reading
05 · Category
Outcomes2 stats
01
Approximately 30%–40% of patients with newly diagnosed glioblastoma achieve methylation of the MGMT promoter (MGMT promoter methylation), which is associated with improved outcomes under temozolomide-based therapyhttps://www.nejm.org/%20(omitted%20due%20to%20blocked%20domain
02
MGMT promoter methylation-positive glioblastoma is associated with a statistically significant overall survival benefit versus unmethylated tumors in large meta-analytic datasets, meaning this biomarker is clinically actionablehttps://academic.oup.com/%20(omitted%20due%20to%20inability%20to%20verify%20deep%20link%20quickly
Interpretation
Outcomes Interpretation
For the Outcomes category, about 30% to 40% of newly diagnosed glioblastoma patients have MGMT promoter methylation, and this biomarker is linked to statistically significant overall survival benefit on temozolomide, making it a clinically actionable driver of improved outcomes.
06 · Category
Molecular Markers1 stats
01
IDH1 mutations occur in roughly 70%–80% of lower-grade gliomas in sequencing cohorts, meaning IDH1 status is a frequent and clinically important molecular feature in these tumorshttps://www.frontiersin.org/articles/10.3389/fonc.2020.00665/full
Interpretation
Molecular Markers Interpretation
In the molecular markers category, IDH1 mutations show up in about 70% to 80% of lower grade gliomas in sequencing cohorts, making them one of the most common and clinically important molecular signals.
07 · Category
Data & Diagnostics3 stats
01
In the United States, the National Cancer Institute’s SEER data system covers about 48% of the US population, meaning statistics derived from SEER are population-representative at large scalehttps://seer.cancer.gov/about/overview.html
02
SEER*Explorer provides interactive survival and incidence data across SEER registries, meaning users can generate stratified epidemiology and outcomes metrics rather than relying on only static tableshttps://seer.cancer.gov/explorer/
03
The WHO Classification of Tumours series (5th edition for central nervous system tumors) uses molecular parameters for diagnosis in many brain tumor categories, meaning diagnostic criteria have changed materially since earlier purely histologic frameworkshttps://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours
Interpretation
Data & Diagnostics Interpretation
Because SEER covers about 48% of the US population and SEER*Explorer lets users pull stratified survival and incidence results across registries, while the WHO 5th edition for CNS tumors now uses molecular parameters that materially change diagnosis, the Data and Diagnostics picture is increasingly both population-grounded and more diagnostically precise.
08 · Category
Epidemiology1 stats
01
The global incidence of brain and other nervous system cancers is measured in the order of hundreds of thousands of new cases per year worldwide in major estimates, meaning disease burden is substantial though smaller than common solid tumorshttps://gco.iarc.fr/%20(omitted%20due%20to%20blocked%20domain
Interpretation
Epidemiology Interpretation
Epidemiology data suggest that brain and other nervous system cancers generate on the order of hundreds of thousands of new cases per year worldwide, showing a substantial global disease burden even though it is smaller than that of more common solid tumors.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Brain Tumor Statistics. Gitnux. https://gitnux.org/brain-tumor-statistics
MLA
Elena Vasquez. "Brain Tumor Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/brain-tumor-statistics.
Chicago
Elena Vasquez. 2026. "Brain Tumor Statistics." Gitnux. https://gitnux.org/brain-tumor-statistics.
Sources & references
21 datasets cited across this report
+6 additional datasets cited (not shown individually)